Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KRAS-EphA-2-CAR-DC
- Development stage
- Phase 1
- Lead developer
- Chinese PLA General Hospital
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Subcutaneous, Intravenous
01
Overview
KRAS-EphA-2-CAR-DC is an investigational cell therapy designed as a dendritic cell (DC) vaccine expressing a chimeric antigen receptor (CAR) that targets both mutant KRAS and EphA2 antigens. The therapy aims to stimulate the immune system, particularly T cells, to recognize and attack tumor cells harboring these mutations or overexpressing these proteins. It is being studied in combination with immune checkpoint inhibitors for the treatment of locally advanced or metastatic solid tumors, including those with KRAS mutations such as non-small cell lung cancer (NSCLC), pancreatic ductal adenocarcinoma (PDAC), and colorectal cancer. The approach leverages dual targeting to potentially enhance anti-tumor efficacy by addressing tumor heterogeneity[1][2][5].
- Other names
- KRAS-EphA-2-CAR-DC vaccineKRAS-EphA2-CAR-DC vaccineKRAS-EphA 2-CAR-DC vaccine
02
Targets
EPHA2 (Ephrin type-A receptor 2)
Beyond the preview
Go deeper on KRAS-EphA-2-CAR-DC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KRAS-EphA-2-CAR-DC.